Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7294081 | 0.98 | HRH3 (0.61) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7282651 | 0.98 | HRH3 (0.61) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7381950 | 0.98 | HRH3 (0.61) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7294419 | 0.98 | HRH3 (0.61) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL678788 | 0.98 | HRH3 (0.61) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL10691862 | 0.98 | HRH3 (0.61) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7290189 | 0.98 | HRH3 (0.61) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7382943 | 0.96 | HRH3 (0.65) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL7281275 | 0.96 | HRH3 (0.65) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 | |
| SCHEMBL10695726 | 0.96 | HRH3 (0.65) | MAPTHRH3CYP1A2MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160192-B1 | ANTIMICROBIAL MATERIALS AND COATINGS | COVIDIEN LP (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20170096391-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2017-04-06 | — | — | US | disclosed |
| US-9586901-B2 | Lactams | UNILEVER PLC (GB) | 2017-03-07 | — | — | US | disclosed |
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| EP-2177226-B1 | Hydroxamate compositions | COVIDIEN LP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130190377-A1 | Novel Lactams | BIOSIGNAL LIMITED (AU) | 2013-07-25 | — | — | US | disclosed |
| US-8425972-B2 | Antimicrobial materials and coatings | COVIDIEN LP (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2564859-A1 | Hydroxamate compositions | Covidien LP (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8153741-B2 | Furanone copolymers | TYCO HEALTHCARE GROUP LP (US) | 2012-04-10 | — | — | US | disclosed |
| US-8071691-B2 | Furanone endcapped polymers | TYCO HEALTHCARE GROUP LP (US) | 2011-12-06 | — | — | US | disclosed |
| EP-0464517-A2 | Amino acid derivatives with renin inhibiting activity | MERCK PATENT GmbH (DE) | 1992-01-08 | — | — | EP | disclosed |
| EP-0456039-A2 | Renin inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1991-11-13 | — | — | EP | disclosed |
| EP-0446751-A1 | Glycolic acid derivatives | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0446485-A2 | Peptide analogues with renininhibiting activity | MERCK PATENT GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
| EP-0339483-A2 | Renin inhbiting amino-acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-02 | — | — | EP | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| EP-0297496-A2 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-01-04 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190377-A1 | Novel Lactams | SULT1E1, PGLS, Q6ZSR9 | MAPT 2960/4885HRH3 3268/4885CYP1A2 284/4885 |
| US-20170096391-A1 | NOVEL LACTAMS | SULT1E1, PGLS, Q6ZSR9 | MAPT 2960/4885HRH3 3268/4885CYP1A2 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.